BPC 157 Oral Tablets, as an emerging potential therapeutic approach, have gradually attracted people's attention. BPC-157 is a peptide substance with unique biological activity, initially isolated from gastric juice. Its oral tablet form provides a relatively convenient way for people to consume it. It has multiple mechanisms that promote tissue repair at the cellular level. It can stimulate the proliferation and migration of fibroblasts, which are important cells in connective tissue responsible for synthesizing collagen and other extracellular matrix components during wound healing. By promoting the activity of fibroblasts, BPC-157 helps accelerate the healing process of wounds and enhance the strength and elasticity of tissues. In addition, it can regulate the process of cell apoptosis, reduce unnecessary cell death, thereby protecting healthy cells in damaged tissues and providing a more favorable cellular environment for tissue repair.
We not only provide pure powder and capsules, but also other dosage forms. If necessary, please contact our sales team.
Our products
|
|
|
|
|
|
|
BPC 157 COA
BPC 157 Oral Tablets (Body Protecting Compound-157) is a synthetic peptide consisting of 15 amino acids. Initially, gastrin fragments were isolated from human gastric juice, and then mass-produced through laboratory synthesis techniques. Its chemical formula is C62H98N16O22, with a molecular weight of 1419.54 g/mol and a CAS number of 137525-51-0. As a dietary supplement or research compound, the production of BPC-157 Oral Tablets requires strict adherence to peptide synthesis, formulation processes, and quality control standards.
Raw material preparation: peptide synthesis and purification
Synthetic method
The synthesis of BPC-157 adopts solid-phase peptide synthesis (SPPS) technology, using Fmoc (9-fluorenylmethoxycarbonyl) or Boc (tert butoxycarbonyl) as the amino protecting group, and gradually condensing amino acids to form peptide chains. For example, starting from the C-terminus (carboxy terminus), the first amino acid is fixed on a resin carrier, and subsequent amino acids are added sequentially. Each step requires deprotection, washing, and coupling, and finally the peptide chain is cut from the resin.
Purification process
Crude peptide processing: The synthesized crude peptide contains impurities (such as unreacted amino acids and protective group fragments), which need to be separated and purified by high performance liquid chromatography (HPLC) or counter current chromatography (CCC). For example, using a C18 reverse phase chromatography column with acetonitrile water as the mobile phase, gradient elution of the target peptide is performed.
Purity standard: Pharmaceutical grade BPC-157 must have a purity of over 98% and be tested for endotoxins (<0.1 EU/mg), solvent residues (such as DMF<500 ppm), heavy metals (such as lead<10 ppm), and other indicators.
Drying and Storage
The purified BPC-157 needs to be freeze-dried to remove moisture and obtain a white powdery raw material. The storage conditions are -20 ℃, away from light, and the shelf life is usually 2-3 years to prevent degradation or oxidation.
Preparation process: Oral tablet development
Accessory selection
Fillers: such as microcrystalline cellulose (MCC) and lactose, used to increase tablet volume and hardness.
Adhesives such as hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidone (PVP) promote particle formation.
Lubricants: such as magnesium stearate and talc powder, reduce friction during compression.
Disintegrating agents: such as cross-linked carboxymethyl cellulose sodium (CCNa) and carboxymethyl starch sodium (CMS Na), accelerate the disintegration of tablets in the gastrointestinal tract.
Special excipients: To improve the oral bioavailability of BPC-157, absorption enhancers (such as bile salts) or nanocarriers (such as liposomes, polymer nanoparticles) may be added.
Granulation and compression
Wet granulation: Mix BPC-157 with auxiliary materials, add adhesive solution to make soft materials, sieve and granulate, and dry to form whole granules.
Dry granulation: Directly compressing mixed powders, suitable for peptides sensitive to heat or moisture.
Compression parameters: Control tablet weight (e.g. 5-10 mg of BPC-157 per tablet), hardness (5-15 N), and brittleness (<1%) to ensure stable tablet quality.
Coating technology
Ordinary coating: such as hydroxypropyl methylcellulose coating, improves appearance and masks odors.
Functional coating: such as enteric coating (pH dependent polymer), which allows tablets to be released in specific areas of the intestine and reduces the degradation of BPC-157 by gastric acid.
Quality control: strict testing from raw materials to finished products
Raw Material Testing
Structural confirmation: Molecular weight was confirmed by mass spectrometry (MS), and amino acid sequence was analyzed by nuclear magnetic resonance (NMR).
Purity analysis: HPLC detects the purity of the main peak, and an amino acid analyzer determines the amino acid composition.
Impurity control: Limit the detection of potential impurities (such as missing peptides, oxidation products).
Preparation testing
Content uniformity: The content of each BPC-157 tablet should be within the range of 90% -110% of the labeled amount.
Dissolution rate: Simulate the gastrointestinal environment (such as pH 1.2 hydrochloric acid solution, pH 6.8 phosphate buffer solution), and detect the dissolution rate of tablets within a specified time (such as dissolution rate ≥ 80% within 30 minutes).
Stability test: Accelerated test (40 ℃/75% RH, 6 months) and long-term test (25 ℃/60% RH, 24 months), monitoring changes in tablet appearance, content, dissolution rate, etc.
Microbial testing
It must comply with the standards of the Chinese Pharmacopoeia or USP, such as a total aerobic bacterial count of<1000 CFU/g, mold and yeast count of<100 CFU/g, and no pathogenic bacteria such as Escherichia coli and Salmonella should be detected.
Production standards and compliance
The production workshop must comply with the Good Manufacturing Practice (GMP) for pharmaceutical production, including the division of clean areas (such as D-level areas), environmental monitoring (such as dust particle count and microbial count), equipment cleaning validation, etc.
Dietary supplements: In the United States, they must be registered under the Dietary Supplement Health and Education Act (DSHEA) and labeled as "This product is not intended to diagnose, treat, cure, or prevent any disease.
Research compounds: If used for preclinical studies, they must be approved by the Institutional Review Board (IRB) to ensure that animal or human trials comply with ethical standards.
It is necessary to clearly label the ingredients, usage and dosage (such as 1-2 times a day, 1 tablet per time), storage conditions, production date, expiration date, manufacturer information, etc. For example, the label of a certain brand of BPC-157 oral tablets states "Each tablet contains 5 mg of BPC-157, recommended to be taken with meals and avoid fasting".
Technical Challenges and Solutions
Low oral bioavailability
Challenge: Peptide drugs are easily degraded by gastric acid and digestive enzymes, with high molecular weight and poor lipid solubility, making it difficult to penetrate the intestinal mucosa.
Structural modification: such as combining BPC-157 with fatty acids or polyethylene glycol (PEG) to improve stability and permeability.
Nanotechnology: Developing carriers such as nanoparticles and liposomes to promote absorption through endocytosis.
Absorption enhancers: Adding bile salts, surfactants, etc. temporarily opens tight junctions between intestinal epithelial cells.
Poor stability of the formulation
Challenge: BPC-157 is sensitive to temperature, humidity, and light, and is prone to hydrolysis or oxidation.
Optimize prescription: Choose inert excipients (such as mannitol, sucrose) as stabilizers.
Packaging design: Adopting double aluminum bubble wrap packaging, with built-in desiccant, stored away from light.
Process control: Shorten production cycle and reduce exposure time to adverse environments.
Market Status and Future Trends
Market supply
Price range: The price of BPC-157 raw materials varies depending on purity and specifications, such as 98% purity, 1g package price of about 1500-3000 yuan; The price of oral tablets varies depending on the brand and dosage. For example, the price of 30 tablets per bottle (5 mg per tablet) is about 500-1000 yuan.
Suppliers: Major domestic manufacturers include Zhejiang Paiti Biotechnology, Hubei Henghua Technology, etc. The products are sold through chemical reagent platforms (such as ChemicalBook) or e-commerce platforms (such as Taobao).
Research Progress
Preclinical studies: Animal experiments have shown that BPC-157 can accelerate the healing of tendons, ligaments, muscles, and bones, alleviate symptoms of inflammatory bowel disease (IBD), and protect the liver and heart from toxic damage.
Clinical trials: Currently, there is a lack of large-scale randomized controlled trials (RCTs) data, but small-scale studies have shown good safety and mild side effects (such as gastrointestinal discomfort and headache).
Future Direction
Formulation innovation: Developing sublingual tablets, oral disintegrating tablets (ODT), etc. to bypass first pass effects and improve bioavailability.
Combination therapy: Used in combination with growth factors (such as IGF-1, EGF) or anti-inflammatory drugs (such as ibuprofen) to enhance therapeutic efficacy.
Personalized medicine: Based on genetic testing or metabolomics, customize BPC-157 dosage and treatment course.
Hot Tags: bpc 157 oral tablets, China bpc 157 oral tablets manufacturers, suppliers, Botulinum Toxin Injection 100iu, Nad Capsule, Nad Peptide Injection, Nad Tablet, BPC 157 Peptide Cream, BPC 157 Peptide Capsules
